Recent advancements harness natural CRISPR-associated transposons (CASTs) to improve one-step, targetable genome editing with enhanced biomedical applicability. Screening methods have been optimized to overcome challenges in adapting CASTs for therapeutic use, substantially increasing editing precision and efficiency. These developments promise to accelerate gene editing strategies across research and clinical applications, expanding tools available for complex genetic engineering.